

JOHNS HOPKINS  
UNIVERSITY

School of Medicine

Office of Technology Licensing  
2024 E. Monument Street, Suite 2-100  
Baltimore MD 21205  
(410) 955-4666 / Fax (410) 955-1245  
otl@welchlink.welch.jhu.edu

RECEIVED  
SEP - 4 1997

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

APA a/c sde  
19/4

September 3, 1997

Jorge A. Goldstein  
Sterne, Kessler, Goldstein, & Fox PLLC  
1100 New York Avenue  
Suite 600  
Washington, DC 20005-3934

RE: Invention entitled **DD3: A Novel Prostate-Specific Gene,  
Overexpressed in Prostatic Tumors** by Dr. William Isaacs, et.al.  
JHU Ref.: DM-3173; Your Ref.: 1619.0010000

Dear Mr. Goldstein:

As a follow-up to my letter of June 11, 1997 I wish to inform you that JHU will not convert the provisional application filed last September 19, 1996 to a regular US application. The material in the application does not have significant commercial potential, particularly in view of an application which contains the entire DD3 gene sequence. We do not consider an application to a partial gene sequence a completed invention and file only upon completion of the sequence. As such we still consider Dr. W. Isaacs to be a co-inventor on any application claiming the entire sequence and to any prostate specific applications.

Sincerely,



Nina Ossanna, Ph.D.  
Associate Director  
Office of Technology Licensing  
nossanna@welchlink.welch.jhu.edu

:cdr

cc: Dr. William Isaacs  
Sue O'Hata (National Institutes of Health and Technology Resources)



BEST AVAILABLE COPY